参考文献:
1. Gupta A, et al. Treat to Target: The Role of Histologic Healing in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2020 Sep 30:S1542-3565(20)31376-8.
2. Fernando Magro et al. ECCO Position Paper: Harmonization of the Approach to Ulcerative Colitis Histopathology. Journal of Crohn's and Colitis, 2020, 1503–1511.
3. Arianna Dal Buono et al. Histological healing: should it be considered as a new outcome for ulcerative colitis? Expert Opinion on Biological Therapy. DOI: 10.1080/14712598.2020.1701652.
4. 葛文松. 炎症性肠病治疗目标的演变. 中华消化病与影像杂志(电子版). 2019.9(5):199-202.
5. Laurent Peyrin–Biroulet et al. Histologic Remission: The Ultimate Therapeutic Goal in Ulcerative Colitis? Clinical Gastroenterology and Hepatology 2014;12:929–934.
6. R.V. Bryant et al. Systematic review: Histological remission in inflammatory bowel disease. Is'complete’remission the new treatment paradigm? An IOIBD initiative. Journal of Crohn's and Colitis (2014) 8, 1582–1597.
7. Marchal Bressenot Aude et al. Which evidence for a treat to target strategy in ulcerative colitis? Best Practice & Research Clinical Gastroenterology (2018), doi: 10.1016/j.bpg.2018.05.001.
8. Rish K. Pai et al. Complete Resolution of Mucosal Neutrophils Associates With Improved Long-Term Clinical Outcomes of Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology (2020),doi:https:///10.1016/j.cgh.2019.12.011.
9. Bruce E. Sands et al. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. N Engl J Med 2019;381:1215-26.
10. Hyuk Yoon et al. Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients with Ulcerative Colitis: A Systematic Review and Meta-Analysis. Gastroenterology (2020), doi:https:///10.1053/j.gastro.2020.06.043.
11. Robert V Bryant et al. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut 2015;0:1–7. doi:10.1136/gutjnl-2015-309598.